摘要
目的研究哮喘-慢阻肺重叠综合征(ACOS)患者应用异丙托溴铵联合布地奈德福莫特罗治疗的效果。方法 88例ACOS患者,按随机数字表法分为观察组与对照组,各44例。所有患者均行吸氧、抗感染等常规治疗,在此基础上,对照组用异丙托溴铵治疗,观察组用异丙托溴铵联合布地奈德福莫特罗治疗。比较两组治疗效果、治疗前后炎症因子水平、肺功能指标。结果观察组治疗总有效率95.45%,高于对照组的75.00%,差异有统计学意义(P<0.05)。治疗后,观察组白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、C反应蛋白(CRP)和肿瘤坏死因子-α(TNF-α)水平分别为(60.11±20.15)pg/ml、(0.38±0.16)pg/ml、(3.77±0.68)mg/L、(56.35±6.55)mg/ml,均低于对照组的(68.54±18.26)pg/ml、(0.45±0.12)pg/ml、(4.25±0.87)mg/L、(60.28±7.33)mg/ml,差异有统计学意义(P<0.05)。治疗后,观察组用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC水平均高于对照组,差异有统计学意义(P<0.05)。结论 ACOS患者应用异丙托溴铵联合布地奈德福莫特罗治疗,可有效改善患者肺功能,减轻机体炎症反应。
Objective To study the effect of ipratropium bromide combined with budesonide and formoterol on serum inflammatory factors and lung function in patients with asthma-COPD overlap syndrome(ACOS).Methods A total of 88 ACOS patients were divided into observation group and control group according to random numerical table,with 44 cases in each group.All patients received routine treatments of oxygen inhalation and anti-infection.The control group was treated with ipratropium bromide,and the observation group was treated with ipratropium bromide combined with budesonide and formoterol.The therapeutic effect,inflammatory factor levels and lung function indicators before and after treatment were compared between the two groups.Results The total effective rate 95.45%of the observation group was higher than 75.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of interleukin-4(IL-4),interleukin-6(IL-6),C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)of the observation group were(60.11±20.15)pg/ml,(0.38±0.16)pg/ml,(3.77±0.68)mg/L,(56.35±6.55)mg/ml,which were lower than(68.54±18.26)pg/ml,(0.45±0.12)pg/ml,(4.25±0.87)mg/L,(60.28±7.33)mg/ml of the control group,and the difference was statistically significant(P<0.05).After treatment,the forced vital capacity(FVC),forced expiratory volume in the first second(FEV1),FEV1/FVC of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).Conclusion Combination of ipratropium bromide and budesonide and formoterol can effectively improve the lung function of patients with ACOS,and reduce their inflammatory reactions.
作者
马亮
MA Liang(Dashiqiao Central Hospital,Dashiqiao 115100,China)
出处
《中国现代药物应用》
2021年第12期134-136,共3页
Chinese Journal of Modern Drug Application
